Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease

Meets major clinical development milestone for lead compound Hoboken, NJ — December 21, 2010 — Anavex Life Sciences Corp. (“Anavex”, AVXL:OB) announced today that it has filed the regulatory submission for ANAVEX 2-73  with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead…